Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11201864 | 0.86 | GAA (0.44) | GAADHODHCYP3A4CYP2D6LMNA | |
| SCHEMBL7432049 | 0.86 | PKM (0.43) | GAADHODHPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1245810 | 0.85 | GAA (0.43) | GAADHODHCYP3A4CYP2D6LMNA | |
| SCHEMBL4147861 | 0.85 | GAA (0.43) | GAADHODHCYP3A4CYP2D6LMNA | |
| SCHEMBL4740015 | 0.85 | POLB (0.44) | GAADHODHPOLBCYP3A4CYP2D6 | |
| SCHEMBL7451703 | 0.84 | SMN1; SMN2 (0.50) | GAADHODHCYP3A4CYP2D6LMNA | |
| SCHEMBL395325 | 0.83 | DHODH (0.46) | GAADHODHSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11198146 | 0.82 | GAA (0.41) | GAADHODHCYP3A4CYP2D6LMNA | |
| SCHEMBL2654421 | 0.82 | EPHX2 (0.42) | GAADHODHPOLBCYP3A4CYP2D6 | |
| SCHEMBL4739345 | 0.81 | MAPT (0.47) | GAADHODHPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2008093940-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION PROCESS FOR THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | GAA 1404/4885DHODH 361/4885POLB 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.